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Abstract
Glioma is a common type of primary brain tumor that represents 28% of all brain tumors and 80%
of malignant tumors. According to a recent study by the Centers for Disease Control and
Prevention (CDC), gliomas account for 53%, 35% and 29% of all brain tumors (68%, 74% and
81% of malignant brain tumors) among children (aged 0-14), teenagers (aged 15-19) and young
adults, respectively. Gliomas are often diagnosed through radiological imaging and
histopathology. There are two main groups of gliomas following World Health Organization’s
classification: Low grade gliomas (LGG), or grade I and II gliomas; and high grade gliomas
(HGG), or Grade III and IV gliomas. This study focuses mainly on LGG due to its long term risks,
such as recurrences and malignant transformations. Although the 5-year mortality rate for LGG
patients is relatively high (17.6%), several studies reported that the average 5-year recurrence rate
is up to 55%. However, there is currently limited guidelines for post-treatment management for
LGG patients. This research aims to estimate the recurrence, malignancy transformation, and
mortality risks for LGG patients who have had an initial treatment in order to have a better
understanding of disease progression. These risk estimates can be incorporated in the development
of a natural history model that can then be used in evaluating and optimizing post-treatment
management strategies for LGG patients in future research.
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Background and Motivation
The number of brain tumor cases has increased about 140% in the U.S. and Europe between 1979
and 2003 (Lorenzi, 2003). Gliomas, a type of primary brain tumor, arise from glial cells. The
etiology of gliomas still remains unknown. Every year in the U.S., there are more than 35,000
people diagnosed with primary brain tumors. According to Ostrom et al. (2014), gliomas are
identified to be one of the most common types of brain tumors and are the most common type of
malignant tumors among younger populations. Gliomas represent 28% of all brain tumors and
80% of malignant brain tumors. In addition, gliomas account for 53%, 35% and 29% of all brain
tumors (68%, 74% and 81% of malignant tumors) among children (0-14 years of age), teenagers
(15-19 years of age) and young adults, respectively.
There are two main groups of gliomas, low grade gliomas (LGGs) and high grade gliomas
(HGGs). LGGs consist of grade I and Grade II gliomas, while Grade III and Grade IV gliomas
are referred to as HGGs, as defined by the World Health Organization (WHO). Although WHO
grade I and II gliomas are grouped as LGGs, grade I gliomas can be cured surgically but Grade II
gliomas remain a challenge for physicians (Pouratian & Schiff, 2010). In this research, we refer
LGGs to Grade II gliomas.
Figure 1 shows the age distribution among 280 glioma patients with gray bars for LGG and
black bars for HGG (Ye, Yang, Geng, Zhou, & Chen, 2002). It is shown from this graph that LGGs
occur most between the ages of 30 and 39. This matches other reported statistics in the literature.
For example, in Pallud et al. (2013), the average age of LGG patients at diagnosis, in a sample of
407 patients, is 39.0 ± 11.0 years. In Schomas et al. (2009), for a patient population of 314 adults,
the median age at diagnosis is 36 years. In Chaichana et al. (2010), for a patient population of 191,
1

the mean patient age is 34.9 ± 15.3 years. In our study, we assume the ages of the patients to be as
in the distribution shown in Figure 1.

Figure 1 Age distribution for all glioma patients (gray: LGG, black: HGG) (YE ET AL., 2002)

There are several review papers on LGGs in the literature in the past few decades (Recht
& Bernstein, 1995; Stieber, 2001; Grier, 2006; Sanai, Chang, & Berger, 2011; Forst, Nahed,
Loeffler, & Batchelor, 2014). These review articles often describe LGGs’ epidemiology,
prognostic factors, their incidence, current diagnostic methods and treatment and follow-up plans,
along with some long term risks of recurrence and malignant transformation.
1.1

Management of Low Grade Gliomas

Low-grade gliomas (LGGs) are a heterogeneous group of neoplasms more prevalent in younger
patient populations. LGGs present a unique challenge for patients and physicians as most patients
will survive a decade or more and may be at a higher risk for treatment-related complications. The
management of gliomas includes diagnosis, treatment decisions, and follow-up decisions.
Although treatment can effectively control the growth of tumors, there is always some amount of
2

residual left after treatment. Residual tumors are normally progression-free and do no additional
harm to the patient (Chaichana et al., 2010; Schomas et al., 2009). From clinical studies in recent
years, some cases of LGGs are identified to manifest more aggressive clinical behaviors, and
require earlier and more aggressive interventions. As quoted from Dr. Susan Chang from
University of California at San Francisco “the natural history of low-grade gliomas is that they
will progress, and over enough time will progress to a higher grade”, we can see that the
“management of LGGs is one of the most controversial areas in neuro-oncology” (Rees et al.,
2008). The remainder of this section discusses how gliomas are diagnosed and treated (Section
1.1.1). Recurrence and mortality risks for LGG patients are introduced in Section 1.1.2.
1.1.1 Diagnosis and treatment
Gliomas are often diagnosed through radiological imaging and histopathology (Grier, 2006).
Gliomas are graded under their pathologic evaluation and follow the standards of the World Health
Organization (WHO). WHO classifies gliomas according to their predominance and grades them
by the presence or absence of necrosis, mitotic, figures, nuclear atypical, and anthelia cell
proliferation (Sanai et al., 2011).
Following diagnosis, there are several treatment options available. The most common
treatment methods are resection and radiation therapy (McGirt et al., 2008; Recht & Bernstein,
1995; Stieber, 2001). Gross total resection by opening craniotomy, is the ideal procedure among
all surgery options for treating LGGs (Sanai et al., 2011; Soffietti et al., 2010; Stieber, 2001).
While surgery and radiation are still recommended as the first-line treatment of LGGs,
chemotherapy (CT) is often considered as a second-line treatment.

3

1.1.2 Recurrence and Follow-up
Although treatment can effectively control the growth of a tumor, there is always residual left after
treatment. Residual tumors are normally progression-free and do no additional harm to the patient
(Chaichana et al., 2010; Schomas et al., 2009). However, there is always a possibility of recurrence
and malignant transformation. LGGs recur when there is an increment in tumor size. Several
studies reported the average 5-year recurrence rate as 50-55% (Chaichana et al., 2010; Schomas et
al., 2009). A recurrent tumor can either have the same properties as the original tumor before the
first treatment, or transform to a malignant tumor. A progressive LGG can cause highly concerning
morbidity, and inevitably lead to death (Pouratian & Schiff, 2010).
Malignant transformation happens when an LGG transforms to have characteristics of an
HGG. Upon recurrence, tumor can also progress as an LGG first and transform to HGG later.
Maher et al. (2001) claimed that Grade II tumors are low-grade malignancies that may follow a
long clinical course but are not curable by surgery. Astrocytoma, a common type of LGG, within
5-10 years, can transform to Glioblastoma, a type of HGG. In addition, HGG patients are 46 times
more likely to die than the general population controlling for age, sex and year (Smoll & Hamilton,
2014). HGG patients usually die due to cerebral edema, a swelling in the brain caused by excessive
fluid, or increased intracranial pressure (Krex et al., 2007).
Although the risks of tumor recurrence and malignant degeneration after resection exist,
there is still no agreement on the estimates for these risks. According to Pignatti (2002), recurrence
rates and malignant transformation rates seem to correlate with the initial sizes and residual sizes
of tumors. Moreover, tumor growth rates inversely correlate with the overall survival (OS) rates
and progression-free survival (PFS) rates. According to the National Cancer Institute (NCI), OS is
the length of time the patient is alive since either the date of diagnosis or the start of treatment for
4

a disease. PFS is the “length of time during and after the treatment of a disease that a patient live
with the disease but it does not get worse”. Table 1 shows some statistics of survival rates for some
common LGGs. It can be seen that survival rates are highly correlated with patient ages.
Table 1: The overall survival rate from CBTRUS report
Average age

Relative 2-yr SR

Relative 5-yr SR

Relative 10-yr SR

at diagnosed

(%)

(%)

(%)

17

91.4

87.6

8.3

42

79.1

64.3

47.0

Mixed Gliomas

40

73.7

57.7

40.5

Asrocytoma, NOS

47

34.1

27.2

23.0

Histology
Pilocytic
Astrocytoma,
Oligodendroglioma

Note: SR = survival rate
From clinical studies in recent years, some cases of LGGs are identified to manifest more
aggressive clinical behavior, and require earlier and more aggressive interventions. Figure 2
(Mainio et al., 2006) shows the probabilities of death from LGGs as compared to HGGs and other
benign tumors (in a sample size of 101 patients) over a 10-year follow-up period. It can be seen
that 23.3% of the patients with a benign brain tumor, 63.2 % of the patients with LGG, and 95.5%
of the patients with HGG died at the end of the follow-up. The mean survival time is 11.6, 9.1 and
1.9 years for benign brain tumor, LGG, and HGG patients, respectively. Although the survival
time of LGG patients is relatively long, the majority of these patients still die from gliomas, and
thus, follow-up decisions can be complicated (Grier, 2006; Maher et al., 2001).

5

Figure 2 Survival Time after Operation (MAINIO ET AL., 2006)
After surgery, in order to detect recurrence, MRI with contrast enhancement is the gold
standard to monitor LGGs. MRI can also predict malignant transformation (Soffietti et al., 2010).
According to Drevelegas and Papanikolaou (2011), sensitivity of MRI appears to be 98% for
lesions larger than 1cm, and 77% for lesions smaller than 5 mm.
1.2

Research Objectives

In this research, we seek to estimate the risks associated with transitions into recurrence,
malignancy transformation and mortality for LGG patients upon their first successful treatment.
These risks quantify disease progression as represented by transition probabilities over time. These
estimates can be incorporated in the development of a natural history model for LGG recurrence
in future research. Medical decisions for improving patient outcomes can then be evaluated or
optimized using the natural history model for a better LGG post-treatment management.

6

Risk estimation
In this section, we present the methodologies for risk estimation that quantify LGG recurrence,
malignancy transformation and mortality over time. We first introduce the disease pathway for
treated LGG patients (Section 2.1), and then illustrate the methodologies for estimating the risk of
transitions into each of the states along the pathway (Section 2.2 – 2.5). We denote the risks of
transitioning to a state at period 𝑡 as the probability of transitioning to the state during time
𝑡 and 𝑡 + 1.
2.1

Disease Pathway

The disease pathway for LGG patients after the first-line of treatment is shown in Figure 3. After
the first-line of treatment, the patient is considered to be in the progression-free state (State 0),
which means the tumor is not progressing or expanding. When the tumor starts to grow again, i.e.,
recurrence appears, the patient will move to the tumor recurrence state (State 1). Note that in most
cases, recurrent LGG tumors grow at the same rate as before the initial treatment (Pallud et al.
2013). The malignant transformation (State 2) occurs in two cases: (1) the growth rate of the
recurrent tumor is very high, and (2) the spread of the tumor cells toward other areas of the brain
is fast (i.e., metastasis occurs). We assume that death from brain tumor (State 3) can only happen
from a malignant tumor (from State 2). The alive patient may also die from another cause (State
4) in the next period. Table 2 explains the parameters being estimated in our risk estimation. The
first column contains the notations while the second column explains their meanings. The third
column summarizes the sources for risk estimation, and the corresponding subsection for each risk
estimation is shown in the last column. It should be noted that in this study, all risk estimations
rely on the information published in the literature. Nevertheless, we have done an extensive
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literature review to identify the most appropriate sources in order to reduce the bias as much as
possible.

Tumor
Recurrence (1)

Progression
Free (0)

Malignant
Transformation
(2)

Death by Brain
Tumor (3)

Death from
another Cause
(4)

Figure 3 Transition between different health states
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Table 2 Input data sources
Model parameter description

Model
parameter

Data source

Section

Probabilities:
𝑃01

- Chainacha et al., 20010

- 2.1

𝑃02

- Pallud et al. (2013)

- 2.2

- Malignant transformation
from recurrence

𝑃12

- Pallud et al. (2013); Rees et al. (2008)

- 2.3

- Death from brain tumor

𝑃23

- Schomas et al. (2009) and Davidoff LM, (1940)

- 2.4

- Death from other causes

𝑃04 , 𝑃14 , 𝑃24

- Arias (2010)

- 2.5

- Recurrence from
progression-free
- Malignant transformation
from progression-free

2.2

Risks of Recurrence from Progression-free (𝑷𝟎𝟏 )

Kaplan Meier survival curves (Kaplan & Meier, 1958) are extensively used in medical studies on
chronic diseases including brain tumors that follow patients over time with the main goal to
understand the mortality risk associated with a specific disease or the treatment of such a disease.
These Kaplan Meier (KM) survival curves are usually derived with large samples that are
representative of a population. Due to the popularity of KM, we intent to use KM curves as the
base for the estimation of 𝑃01 and 𝑃02 .
2.2.1 Study Summary
The probability of a patient transitioning from a progression-free state at time 𝑡 to the tumor
recurrence state at time 𝑡 + 1 is estimated using published survival curves derived by Chaichana
et al. (2010) after a 144-month follow-up of 191 patients who had undergone surgery for LGGs at
a single academic tertiary-care institution. According to Chaichana et al. (2010), the 5- and 8-year
progression-free survival rates were 44 and 24%, respectively, and the 5- and 8-year malignancy9

free survival rates were 74 and 56%, respectively. A patient who has not had an LGG recurrence
from his initial treatment is considered progression-free. Similarly, a living patient without a
malignant tumor after initial treatment is considered malignant-free. Figures 4A and 4B
demonstrate the progression-free survival (PFS) and malignant-free survival (MFS) KM curves
over the course of 144 months from their study. In order to obtain specific data points from this
figure to estimate risk changes over time (i.e., transition probabilities every six months), we
reconstruct the figure and use the information from this reconstruction for a curve fitting. The
results of the curve fitting are then used to calculate the probabilities.

B

A

Figure 4 (A) Progression-free survival curve; (B) Malignant-free survival curve (CHAICHANA ET
AL., 2010)

2.2.2 Data Reconstruction
The number of individuals at risk just prior to time t can be seen as the number of individuals in
the sample who neither died nor were censored prior to time t. Because in the paper (Chaichana et
al., 2010), no censoring (a form of missing data problem (Guyot, Ades, Ouwens, & Welton, 2012))
was presented or mentioned, we assume that the total number censored is zero. The software
WebPlotDigitizer (Ankit Rohatgi, n.d.) was used to create a list of associated data points from the
10

curves. The initial number of patients (191) and the ending number of patients by the end of years
reported in Chaichana et al. (2010) are used for estimation. An event occurs when a patient leaves
the progression-free survival (PFS) set. The algorithm by Guyot et al. (2012) guides the
construction of a data set from collected data points. This data contains the number at risk and the
number of events over time. Some key statistics of the data after applying Guyot et al. ’s algorithm
are shown in Table 3 and Table 4:

Table 3 Summary of statistic from reconstructed MFS curve
Initial number Number
0.95 LCL 0.95 UCL
Median
of patients
of events
of median of median
191
119
88.7
79.1
99.8
TABLE 4 SUMMARY OF STATISTIC FROM RECONSTRUCTED PFS CURVE
Initial number
of patients
191

Number
of events
145

Median
53.3

0.95 LCL
of median
47.8

0.95 UCL
of median
74.2

Using the reproduced data, KM curves are graphed, as seen in Figure 5. Comparing the
shapes between the original graph (Figure 4) and the reconstructed graph (Figure 5B), the
reconstructed data is deemed close to the original KM curve. The only additional statistics reported
in the paper for validation purpose are the median time to recurrence and median time to malignant
transformation. We justify the quality of the reconstruction and fitting by comparing our produced
numbers with these statistics and discuss in detail in Section 2.1.3.
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1
0.748691099

0.8

A

150

0.586387435

% n.risk

Number of patients

200

100

MFS
PFS

50

0.6

B

0.460732984

0.4
MFS Reconstructed
PFS Resonstructed

0.2

0

0.240837696

0
0

24

48
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96
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144

0

24

48

72

96

120

144

Time (month)

Time (month)

Figure 5 Graphs from reconstructed data from CHAICHANA ET AL. (2010)

2.2.3 Method of Probability Calculation
Let 𝑘𝑡 denote the number of patients who are progression-free and alive at time 𝑡, and let 𝑛𝑡 denote
the number of patients who are malignant-free at time 𝑡 and are alive. If 𝑠 is the total number of
LGG patients, then the number of patients who either have recurrence, malignant transformation,
or die at time 𝑡 is 𝑠 − 𝑘𝑡 . The number of patients who either have malignant transformation or die
at time 𝑡 is 𝑠 − 𝑛𝑡 . We assume that patients only die when they reach the malignancy state.
Therefore, the number of patients with recurrent tumor at time 𝑡 and are alive is 𝑛𝑡 − 𝑘𝑡 . In other
words, the number of patients who experience recurrence at period 𝑡 + 1 and are alive is the
difference between the malignant-free patients and the number of patients who do not have
recurrence and survive at period 𝑡 + 1 . Hence, the probability the patient have recurrence for
period 𝑡 + 1 is assumed to be the number of patients who has recurrence from 𝑡 to 𝑡 + 1 divided
by the total number of patients who are progression-free at time 𝑡 .
In order to estimate the risk changes, we further assume a continuous function and apply
curve fitting to the KM curve. Then, the number of patients that have tumor recurrence at time t is
calculated using (eq.1), and the number of alive patients at time 𝑡 is computed using (eq.2). The
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summary of the results from the fitting (using (eq.1) and (eq.2)) are shown in Figures 6 and 7,
respectively.
The models used to fit the curves resulted with R2 of more than 99% for both functions. QQ plots measure the agreement of a fitted distribution with observed data. The Q-Q plot from
Figure 6 implies that the models can fit the reconstructed MFS data well, assuming that the
reconstructed data comes from a continuous and polynomial function. Similar results can be seen
in Figure 7 for the PFS data. The majority of points lay on the solid line, or stay within the “dotted
bounds”, which confirms that two data sets (reconstructed data set and fitted data set) in each case
(PFS and MFS) come from populations with a common distribution. The graphs between the
reconstructed data and the fitted model (Figures 6A and 7A) do verify that the derived models are
closed to the reconstructed data distribution. Even though we could not compare the median time
to recurrence and malignant transformation from the literature, through equations from regressions
(eq.1) and (eq.2), we were able to find the median of recurrence time to be about 27 months, which
is relatively closed to the literature (28 months as reported in Chaichana et al. (2010)).
𝑛𝑡 = 214 − 2.34𝑡 + 4.05 × 10−2 𝑡 2 − 4.2 × 10−4 𝑡 3 + 1.38 × 10−6 𝑡 4

(eq.1)

𝑘𝑡 = 203 − 1.76𝑡 − 1.35 × 10−2 𝑡 2 + 2.53 × 104 𝑡 3 − 1.01 × 10−6 𝑡 4

(eq.2)

The next goal is to find the probability of tumor recurrence from period (𝑡 − 1) to 𝑡, which
is denoted as 𝑝𝑡01 . Therefore, the probability an event is occurring during an interval is the sum of
the probabilities of occurrence during that interval, which gives 𝑝𝑡01 , the probability of recurrence
at period 𝑡, in (eq.3):

𝑝𝑡01 = {

(𝑛𝑡 −𝑛𝑡−1 )−(𝑘𝑡 −𝑘𝑡−1 )

0

𝑘𝑡−1

if (𝑛𝑡 − 𝑛𝑡−1 ) − (𝑘𝑡 − 𝑘𝑡−1 ) > 0
otherwise.
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(ep.3)

Coefficients:
Estimate

P-value

(Intercept)

2.14E+02

< 2e-16

𝑡𝑖𝑚𝑒

-2.34E+00

1.11E-08

𝑡𝑖𝑚𝑒

2

4.05E-02

8.60E-05

𝑡𝑖𝑚𝑒

3

-4.20E-04

9.22E-05

𝑡𝑖𝑚𝑒 4

1.38E-06

0.000249

𝑅2=

9.92E-01

MFS reconstructed

MFS fit

Number of patients

200
150
100
50

A

B

0
0

24

48

72
96
Time (month)

120

144

Figure 6 Fitting Result For Equation (1)
Coefficients:
Estimate

P-value

(Intercept)

2.03E+02

< 2e-16

𝑡𝑖𝑚𝑒

-1.76E+00

9.21E-11

𝑡𝑖𝑚𝑒 2

-1.35E-02

7.22E-02

𝑡𝑖𝑚𝑒

3

2.53E-04

3.89E-03

𝑡𝑖𝑚𝑒

4

-1.01E-06

0.00257

𝑅2=
PFS reconstructed

Number of patients

200

9.95E-01

Fitted

150
100

B

A

50
0
0

24

48

72
96
Time (month)

120

144

Figure 7 Fitting Result For Equation (2)
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2.2.4 Results and Discussion
The transition probabilities produced from the estimation method in Section 2.1.3 are shown in
Table 5 for the period of 10 years (120 months). We consider a period to be 6 months. Each
probability represents the risk of recurrence in the corresponding period for a progression-free
patient.
Table 5 Recurrence Probabilities over Time
Time (month)

P(recurrence)

Time (month)

P(recurrence)

6

0.078813535

66

0.050190744

12

0.056518543

72

0.043082856

18

0.042414754

78

0.029172641

24

0.034996228

84

0.008009822

30

0.032873925

90

0.000000000

36

0.034685739

96

0.000000000

42

0.039026483

102

0.000000000

48

0.044398714

108

0.000000000

54

0.049191115

114

0.000000000

60

0.051696998

120

0.000000000

The initial transition probability at 6-month is high (0.0788) while it keeps reducing for 48
months (4 years) and, then goes back up to 0.05. For the time between the 60th month (5th year)
and the 78th month (6.5th year) periods, the probabilities decrease again. From the 84th month (7th
year) to the 90th month (7.5th year), there is mostly no risk of recurrence. These behaviors can be
observed from Figure 5, whereas from the 84th month to the 100th month, the slope of PFS is not
as steep as MFS. Then, from the 100th month to the 120th month, all the progress-free patients stay
in the PFS group. In other words, after 90 months (7 years) till the end of 120 months (10 years),
since the tumor is more likely to become malignant and no recurrence is observed during this
period based on the survival curves, the transition probabilities are zero.
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2.3

Risks of Malignant Transformation from Progression-free (𝑷𝟎𝟐 )

2.3.1 Study Summary
We applied a similar approach as described in Section 2.1, using reconstructed data derived from
Pallud et al. (2013)’s published KM curves to estimate the probability of malignant transformation
from progression-free. From Pallud et al., by the end of the follow-up, 209 patients had malignant
transformation, and 87 patients died of brain tumor progression (from either recurrent tumor or
malignant tumor). No censoring is also assumed as no such information is reported in the paper.
Figure 8 presents the KM curves of the overall survival (8A) and the general malignant-free
survival (8B).

A

B

Figure 8 KM estimates of OS and malignant progression-free survival according to velocity of
diametric expansion (Pallud et al., 2013).

2.3.2 Data Reconstruction
Using the same approach presented in Section 2.1.2, we reconstruct the data using the algorithm
by Guyot et al. Figure 9 displays the graph of the reconstructed data. Moreover, the median of the
16

reconstructed MFS curve is 90.8 months, and the median from the original curve is 103; this error
may come from the no censoring assumption. The median from the reconstructed OS curve is 248,
and the median from the original curve is 249 months. The shapes of the reconstructed curve are
closed to the shape of the original KM curve.

1
MFS
OS

Number of patients

400

OS Reconstructed
MFS Reconstructed

0.8

300

% n.risk

0.6

200

0.4

100

0.2

A

B

0

0
0

50

100
150
Time (months)

200

0

250

50

100
150
Time (months)

200

250

Figure 9 Reconstructed KM curves from Pallud et al.

2.3.3 Method of Probability Calculations
Using a similar analysis as in Section 2.1.3, the probability a patient moves to the malignant
transformation state is the fraction of the number of patients who survive and have malignancy at
time t and the total number of patients who did not have malignant tumor at time 𝑡 − 1. Similarly,
a continuous curve fitting is applied for ease of calculations. The same validation procedure as in
Section 2.1.3 verifies that the models in (eq.4) and (eq.5) represent our reconstructed data well.
The Q-Q plots from Figure 10 and Figure 11 implies that our models can implement with our
reconstructed data, assuming that the reconstructed data are continuous. In both MFS and OS
cases, exponential functions are fitted. The first order of the OS function was discarded because
the p-value of the coefficient is not significant (p=0.957).
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In this section, 𝑚𝑡 , 𝑙𝑡 are denoted as the number of malignant-free patients at time t and the
number of alive patient at time t, correspondingly. From fitting the curves, we derive (eq.4) and
(eq.5). The probability of malignant transformation during time (𝑡 − 1) and 𝑡 can be calculated
through (eq.6), which is similar to (eq.3).
𝑚𝑡 = Exp [6.077 −

𝑙𝑡 = Exp [6.12 −

9𝑡
103

2.562𝑡
103

+

−

1.89𝑡 3
107

3.837𝑡 2

−

106

]

8.941𝑡 4
1010

(eq.4)

]

(eq.5)

The next goal is to find the probability of tumor malignant transformation from progression
from period (𝑡 − 1) to 𝑡, which is denoted as 𝑝𝑡02 . The probability is calculated as in (eq.6).
Similarly, the probability an event is occurring during an interval is the sum of the probabilities of
occurrence during that interval, which gives:
(𝑚𝑡 −𝑚𝑡−1 )−(𝑙𝑡 −𝑙𝑡−1 )

𝑝𝑡02 = {

0

𝑙𝑡−1

if (𝑚𝑡 − 𝑚𝑡−1 ) − (𝑙𝑡 − 𝑙𝑡−1 ) > 0
otherwise
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(eq.6)

Coefficient

Estimate

𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡
𝑡𝑖𝑚𝑒
𝑡𝑖𝑚𝑒

2

P-value

6.077

<2E-16

-2.56E-03

<2E-16

-3.84E-06

4.47E-07

𝑅2 = 0.9901
Reconstructed

Fitting model

400
300

A

200

B

100
0
0

100

200

300

Figure 10 Fitting OS for malignant data
Coefficient
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𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡
𝑡𝑖𝑚𝑒

P-value

6.12

<2E-16

-9.57E-03

<2E-16

𝑡𝑖𝑚𝑒

3

1.90E-07

𝑡𝑖𝑚𝑒

4

-8.91E-10

5.29E-09
<2E-16

𝑅2 = 0.9948
500

number of patients

From data
400

From fitting model
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200
100

A

B

0
0

50

100

150

200

250

300

Time

Figure 11 Fitting MFS Probability of malignant transformation from recurrence
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2.3.4 Results and Discussion
The transition probabilities produced from the estimation method are shown in Table 6 for the
period of 10 years (120 months).

Table 6 Malignant transformation probabilities over time
Time
(month)
6

0.037786384

Time
(month)
66

0.020348917

12

0.036718447

72

0.018320041

18

0.035422169

78

0.016355913

24

0.033926502

84

0.014484168

30

0.032260659

90

0.012731505

36

0.03045409

96

0.011123485

42

0.028536426

102

0.00968433

48

0.026537404

108

0.008436708

54

0.024486769

114

0.0074015

60

0.022414148

120

0.006597547

P(malignant)

P(malignant)

As can be seen in the results from Table 6 above, the initial transition probability between 0
and 6 months is the highest (0.037786). The probabilities keep decreasing and at 120th month (10th
year), the probability is 0.0065975. Comparing with the results from the probability of recurrence
from progression-free, the probabilities are smaller up to 90th month (7th year). The probabilities
of malignant transformation after 7th year are greater than the probabilities of recurrence (𝑃01 ).
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2.4

Risks of Malignant Transformation from Recurrence (𝑷𝟏𝟐 )

2.4.1 Summary of Methods
According to Rees et al. (2008), the rate of malignant transformation highly depends on the size
of the tumor’s volume. Moreover, Pallud et al. (2013) believe that the diametric expansion rate of
recurrence is a reliable predictor of early malignant transformation for LGGs. In summary, there
are two factors we need to use in order to find the tumor volume, which determine the risks of
malignant transformation: 1) the residual of the tumor after the first line of treatment, and 2) the
growth rate of the recurrent tumor. Using Pallud et al. (2013)’s tumor growth distribution, we can
calculate the volume of the patient’s recurrent tumor over time, given that the growth rate remains
static. Using the risk prediction from Rees et al. (2009), the probability of malignant transformation
can be estimated.
2.4.2 Obtaining the Volume of Recurrent Tumor
The risk of malignant transformation is dependent on the volume of the tumor at time 𝑡. In this
section, we focus on determining the tumor volume through the growth rate of the recurrent tumor.
Even though the tumor shapes are not the same in every patient, previous studies, such as Pallud
et al. (2013) and Rees et al. (2009), have simplified the growth through diametric expansion rate.
The distribution of velocities of diametric expansion rate from 407 LGG patients (Pallud et al.
2013) (Figure 12) is used to estimate the probability of volume growth during a period when
recurrence occurs.
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Figure 12 Distribution of the 407 patients by individual velocities of diametric expansion
(PALLUD ET AL., 2013)

Following Pallud et al. (2013) and Rees et al. (2008), tumors are assumed to be spherical
to simplify the volume calculation. Denote 𝑉𝑡 (cm3 or ml) as the tumor volume at time t and the
growth rate of the tumor is 𝑣𝐿 (cm/yr). Assuming that the initial diameter of the residual tumor
after the first line of treatment is 𝑑𝑖 (cm), the time (year) the tumor has recurred and the diametric
expansion rate of the recurrent tumor are known, we can calculate the tumor volume at time t as
in eq.7:

𝑉𝑡 =

𝑑 𝑡𝑣
4𝜋( 𝑖 + 𝐿 )
2

3

2

(eq.7)

3

2.4.3 Risk of Malignant Transformation
As previously mentioned, the risk of malignant transformation is significantly dependent on tumor
volume. According to Rees et al. (2009), tumor volumes and growth rates were calculated using
semi-automated segmentation, and analyzed in a hierarchical regression model among twentyseven patients with biopsy-proven, untreated LGGs who had at least three MRI studies at 6 month
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intervals. It is reported that for every 10% increment in tumor volume, after adjustment, risk of
transformation increases by 29% with 95% Confidence Interval (CI) of 10-51%. Comparing the
probability of malignant transformation for tumor volume size 𝑉1 and 𝑉2 (i.e., 𝑟1 versus 𝑟2 ), we
have
r2 = 𝑟1 × 1.29, if 𝑉2 = 𝑉1 × 1.1.
Then, considering number of increments using 𝑛, we have:
𝑟2 = 𝑟1 × 1.29𝑛 , if 𝑉2 = 𝑉1 × 1.1𝑛 .
Therefore,
V2
V1

= 1.1𝑛 and

𝑟2
𝑟1

V

= 1.29𝑛 ,

(eq.8)

𝑟

log1.1 (V2 ) = log1.29 (𝑟2 ) .
1

1

𝑉
log1.1 ( 2 )

𝑟2 = 𝑟1 × 1.29

𝑉1

(eq.9)

Given that after the initial treatment the initial residual radius is 0.75cm and the diametric
expansion is 4.5cm/yr, the maximum tumor volume is 27.6116ml and 113.097ml within 6 months
and 12 months, respectively (obtained from (eq.7)). Table 7 shows the base values we use to
calculate the risks of malignant transformations. In Table 7, because we have multiple volume
values and multiple risk values, but the number of volume values are not enough to fit an equation,
it is best to weight the values when calculating the risks. The difference between two reported
volumes in Table 7 is 20ml, therefore the risks are calculated as in equation 10 with the volume
values, associating with its risks, shown in Table 7. When applying equation 9 with the volumes
in Table 7 to compare our results with reported values from Table 7, the errors obtained are shown
in Table 8. These errors are within the 95% CI, which are between 10-51%. Because the errors are
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within the 95% CI, equation 9, based on information provided from Rees et al. (2008) is okay to
use.
Table 7 Reported tumor volume with its associated risks (REES ET AL., 2008)
Tumor Volume (ml) , 𝑉1
𝑉1𝑎
60
𝑉1𝑏
80
𝑉1𝑐
100
𝑉1𝑑
120
𝑉1𝑒
140
𝑉1𝑓
160

𝑟1𝑎 × 1.29

𝑟2 =

{

(1 −

𝑉2 −𝑉1𝑎

(1 −

𝑉2 −𝑉1𝑏

(1 −

𝑉2 −𝑉1𝑐

20

) (𝑟1𝑎 × 1.29

20

20

(1 −

𝑉2 −𝑉1𝑑

(1 −

𝑉2 −𝑉1𝑒

20

20

𝑉
log1.1 ( 2 )
𝑉1𝑎

) (𝑟1𝑏 × 1.29

) (𝑟1𝑐 × 1.29

𝑉1𝑏

𝑉
log1.1 ( 2 )
𝑉1𝑐

) (𝑟1𝑑 × 1.29
) (𝑟1𝑒 × 1.29

𝑉
log1.1 ( 2 )
𝑉1𝑒

12
34
50
65
77
87

𝑉2 −𝑉1𝑎
20

20

20

)+(

if V2 < 𝑉1𝑎

20

𝑉2 −𝑉1𝑒

𝑉1𝑏

,

𝑉1𝑐

𝑉1𝑑

) (𝑟1𝑒 × 1.29

𝑉
log1.1 ( 2 )

10.23822
2.743955
14.04235
19.2163
34.29712
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) , if V2 ∈ [𝑉1𝑐 , 𝑉1𝑑 )

𝑉
log1.1 ( 2 )

if V2 > 𝑉1𝑓

Error %,
12
months
37.37406
33.48565
37.33991
49.07868
47.90856

) , if V2 ∈ [𝑉1𝑏 , 𝑉1𝑐 )

𝑉
log1.1 ( 2 )
𝑉1𝑒

Table 8 Errors from using equation 8
Error %,
6 months

) , if V2 ∈ [𝑉1𝑎 , 𝑉1𝑏 )

𝑉
log1.1 ( 2 )

𝑉
log1.1 ( 2 )

) (𝑟1𝑓 × 1.29

𝑉1𝑓

𝑉
log1.1 ( 2 )

) (𝑟1𝑐 × 1.29

) (𝑟1𝑑 × 1.29

𝑉2 −𝑉1𝑑

20

,

) (𝑟1𝑏 × 1.29

𝑉2 −𝑉1𝑏

𝑉2 −𝑉1𝑐

)+(

𝑟1𝑓 × 1.29

6
14
25
38
53
67

𝑉1𝑎

)+(

)+(

𝑉
log1.1 ( 2 )
𝑉1𝑑

Risk at 12
months (%)

𝑉
log1.1 ( 2 )

)+(

𝑉
log1.1 ( 2 )

Risk at 6
moths (%)

𝑉1𝑓

) , if V2 ∈ [𝑉1𝑑 , 𝑉1𝑒 )

) , if V2 ∈ [V1e , V1f )

(eq.10)

Finally, using the distribution of growth rate from Pallud et al. (2013) in Figure 12 above,
we can calculate the expected risk of malignant transformation. Given 𝑛𝑖 , the number of patients
who has growth rate 𝑖 (𝑖 = 1 … 45 𝑚𝑚/𝑦𝑟), and 𝑟𝑖 , the probability of transformation for that
growth rate, the weighted probability conditioning on the growth rate of malignant transformation
is:
𝑃 = ∑45
𝑖=1(𝑃𝑖 |𝑑𝑖 ) × 𝑑𝑖

(eq.10)

2.4.4 Results and Discussion
The probability of malignant transformation is dependent on the growth rate of the tumor. The
results for different growth rates are shown below in Figure 13 for the initial tumor radius of
0.75cm and an initial tumor radius of 1cm. To illustrate our calculations, some examples are
provided.
If the residual tumor’s radius is 0.75cm, and the diametric expansion is 4.5mm every 6
4𝜋

months, then in 6 months, from (eq.6) the volume is 𝑉𝑡 = ( 3 ) (0.75 +

0.45 3
2

) = 2.6876 𝑐𝑚3 .

Using the values from Table 7 as base values to estimate the transition probability from recurrence
to malignant transformation, we can apply eq.8 to find the risk of malignant transformation 𝑟2 . If
at recurrence, the growth rate of the patient is 4.5mm/yr, from the initial diameter of 1𝑐𝑚, the
volume of tumor after 6 months will be 𝑉2 = 1.596𝑚𝑙. We know that 𝑟1 = 6% at tumor volume
of 𝑉1 = 60𝑚𝑙. Applying eq. 8, we have:
𝑉
log1.1 ( 2 )
𝑉1

𝑟2 = 𝑟1 × 1.29

2.6876
)
60

⇔ 6 × 1.29log1.1 (
25

= r2 = 0.001494%

The results in Figure 13 shows the results of transformation risks from a recurring tumor
based upon the time, the initial tumor radius and the growth rate. This results show how the growth
significantly affects the risk of transformation. Numerical results are shown in Appendix 1.
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1
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0
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4.00
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0.00

1.00

2.00
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4.00
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Figure 13 Risk of malignant transformation from recurrence tumor

2.5

Risks of Death from other Causes
(𝑷𝟎𝟒 = 𝑷𝟏𝟒 = 𝑷𝟐𝟒 )

A summary of how death from other causes are obtained is shown in Table 9. Using the CDC Life
tables (http://wonder.cdc.gov/ucd-icd10.html), we are able to obtain the risks of death from all
causes (second column) and the risks of death from all CNS neoplasms. The maximal amount of
diagnosed gliomas a year is 80% of all CNS cases. The third column in Table 9 shows 80% of
deaths from CNS neoplasms. Taking the difference between the total death from all causes and
80% of death from CNS, we have the estimated risks of death from other causes. The age groups
are picked based upon the range of age of LGG patients at diagnosis reported in Section 1.
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Table 9 Risks of death from other causes

2.6

Ages

Percentage of death from all causes

Death from CNS neoplasms

80% of CNS

Death from other causes

15-24

0.07400%

0.00000798%

6.38136E-08

0.07399%

25-34

0.10520%

0.00000740%

5.92387E-08

0.10519%

35-44

0.18700%

0.00000935%

7.48233E-08

0.18699%

45-54

0.41900%

0.00001641%

1.31292E-07

0.41899%

Probability of Death from Tumor (𝑷𝟐𝟑 )

2.6.1 Methods of Calculation
A small record was found from Davidoff M.L. (1940), which discloses duration of life, in years,
calculated from the first time gliomas were removed during 1925-1926. Radiation therapy was not
widely applied toward tumor treatment until 1950s (Dept. of Radiation Medicine, n.d.). Therefore,
we can assume that the deaths since initial surgery reported in Davidoff’s table (Table 10) are
natural deaths without any interventions. However, such a small sample of data does not guarantee
accuracy. In other words, the sample size of Davidoff’s data is small, only 48 patients, after deaths
from surgery are taken out. Due to a small sample size, it is hard to justify if the probabilities of
natural death after 2 or 3 years, calculated from Davidoff’s data, is good. Therefore, we used the
current the OS curve, reported from the literature to find the probabilities of natural death from
tumor, after we have compared the difference between Davidoff’s data versus our current OS data.
We cannot use OS curve alone to estimate the probabilities of natural death because the reported
OS data from recent studies may include patients with treatment while being alive. Therefore, we
use the OS reconstructed data from Schomas et al. (2009) to assist with finding the probability of
natural death from Gliomas.
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The probability of death from Gliomas at time 𝑡 for LGG patients is the ratio of the patients
who died within time 𝑡 and 𝑡 + 1 and the number of living patients at 𝑡. Eq. 11 expresses this
formula, where 𝑛𝑡 is the number of living patients at time 𝑡:

𝑃23 =

𝑛𝑡 −𝑛𝑡+1

(eq.11)

𝑛𝑡

We found that the probability of death within 1 year after treatment of LGG from Schomas
et al. is

314−292
314

15

= 0.070064, and the same probability from Davidoff is 62−14 = 0.3125. We see
0.3125

that the ratio between the two probabilities for the first year is 0.070064 = 4.46. This means the
chance of death from having no clinical intervention is 4.46 times higher than having clinical
adjuvant treatment within the first year after the initial treatment. The probability of death between
the first and the second year from Schomas et al. is

292−267
292

= 0.085616. The same probability

4

from Davidoff M.L. is 62−14−15 = 0.12121. We see that the ratio between the two probabilities
0.12121

for the second year is 0.085616 = 1.42. Similarly, we calculated the ratios of the probabilities using
statistics reported from Schomas et al. and Davidoff, and obtained the Table 11. The ratios of the
first year is high (4.46) while the ratios from the 2nd to the 5th years remain less than 2.25. The
average of the ratios is 2.15. We only consider the values of the first 4 years in Davidoff M.L.’s
report because the total number of alive patients dropped significantly at the 5th year compare to
the 1st year (62 − 14 − 15 − 4 − 6 − 4 − 3 =19). A sample size less than 20 is not a good sample
size for estimates. For this study, we use the average to calculate the risks of death.
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Table 10 Gliomas Occurring During 1925-1926: duration of life, in years, (Davidoff M.L., 1940)
Type

Total\time

Death
at
surgery

0-1

1-2

2-3

3-4

4-5

5-6

6-7

7-8

8-9

9-10

Oligodendroglioma

3.00

1.00

0.00

0.00

0.00

0.00

1.00

0.00

0.00

0.00

0.00

0.00

Cyst only

5.00

0.00

2.00

0.00

1.00

0.00

1.00

0.00

0.00

0.00

0.00

0.00

Astroblastoma

6.00

1.00

0.00

0.00

1.00

1.00

0.00

2.00

0.00

0.00

0.00

0.00

Ependymoma

3.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Spogioblastoma

4.00

1.00

1.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Papilloma

2.00

1.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Astrocytoma

19.00

5.00

3.00

2.00

1.00

2.00

0.00

0.00

0.00

0.00

0.00

1.00

Glioblastoma Multiform

12.00

2.00

6.00

0.00

3.00

1.00

0.00

0.00

0.00

0.00

0.00

0.00

Medulloblastoma

5.00

2.00

2.00

1.00

0.00

0.00

1.00

1.00

0.00

0.00

0.00

0.00

Atypical Gliomas

3.00

1.00

1.00

1.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

Total

62.00

14.00

15.00

4.00

6.00

4.00

3.00

3.00

0.00

0.00

0.00

1.00

Table 11 Probabilities comparison between Davidoff M.L. and Schomas's published results
Year

Probability of
death from
Davidoff M.L's

Probability of
death from
Schomas's

Ratio

1.00

0.3125

0.0701

4.46

0.1212

0.0856

1.42

3.00

0.2069

0.0933

2.22

4.00

0.1739

0.1120

1.55

5.00

0.1579

0.1402

1.13

Average of the
ratios=

2.15

2.00
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2.6.2 Results and Discussion
The probability of death from tumor is shown in Table 12
Table 12 Probabilities of death from recurrence tumor
6

Probability of death
from tumor
0.047929936

66

Probability of death
from tumor
0.184946237

12

0.10504886

72

0.139117647

18

0.103082192

78

0.094654088

24

0.077338129

84

0.11025641

30

0.120335821

90

0.101689189

36

0.084980237

96

0.106737589

42

0.089211618

102

0.096268657

48

0.158225108

108

0.10078125

54

0.150700935

114

0.105737705

60

0.140452261

120

0.092672414

Time (month)

Time (month)

From Table 12, we see that the probability of death between 12th month and 42th month
and between 78th month and 120th month for 6-month intervals with recurrence tumors stays about
0.1 . The risk of death from malignant transformation increases if there is recurrence between the
48th month (4th year) and 72th month (6th year).
In this study, we have assumed that malignant patients are patients with tumor transforming
to grades III and IV gliomas. When we compare our probability of death from our results with
probabilities of death from published papers in HGG there were significant differences. Through
reconstructing Silverstein et al. (1996) data, the probability of dying from Grade IV Gliomas with
treatment within 6 months is 0.3125 and the probability of death within 1 year is 0.59375. It
seemed that our probabilities have remained low to include only the patients who have big tumors
but were not highly diffusive, more likely to be Grade III Gliomas. As seen in Figure 14 below,
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the survival curve of Grade IV Gliomas (age < 65)’s curve is a lot steeper compared to the Grade
III Gliomas (age < 65)’s curve.

Figure 14 Survival, stratified by grade of astrocytoma and age of patients (Silverstein et al.,
1996)
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Conclusion and Future Work
This research illustrates the methodologies to calculate risks of recurring LGGs using published
statistics from the literature. We selected the most related studies and used their results to apply
toward our methods. For the probabilities of recurrence and malignant transformation from
progression-free, we exploited published progression-free survival, malignant-free survival and
overall survival curves. We recreated the curves and applied equation fittings in order to find the
probabilities. Probabilities of death from tumor and death from other causes are estimated from
deaths statistics reported.
There are several limitations in this research, which needs to be justified. Firstly, by
assuming censoring is zero for the survival curves, the median of the reconstructed data for MFS
is different (90 months versus 103 months). Secondly, although we tried to validate the results, for
some parameters, there is no additional study that may enable validation. Thirdly, in order to
simplify our risk model, we assumed that malignant patients are patients Grade III and Grade IV
tumors. However, when we compare our probability of death from our results with probabilities
of death from published papers in HGG there were significant differences. Our probabilities have
remained low to include the patients who have big tumors but were not highly diffusive. In the
future work, we would like to separate tumor into specific malignant types, such that tumors with
fast growth, diffusive tumors and tumor which have both characteristics would be considered in
order to make the mortality risks more realistic. Fourthly, in our study, we assumed that patients
only die from the tumors are big or from tumors that are highly diffusive. In reality, patients can
also die from small tumors, but only when the tumors create side effects, such as seizure, blindness,
or immobility.
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To the best of our knowledge, this is the first study that models all possible risks for
different time intervals of recurrent LGGs, despite of the long term risks and the popularity of
LGG among CNS tumor patients. The results of this work may have an important contribution
toward medical decision making community, such that it can be developed toward a natural history
model and be applied toward other models for cost-effectiveness, decision models on follow-up
schedules, or decisions models on treatment time. Moreover, methodologies illustrated in this
research can be applied toward studies of diseases whose data is not readily available or studies of
diseases in the past, whose statistical reports are limited. In the future, we would like to add more
states in our model. High grade tumors should be divided into “fast growth” group, “diffusive”
group, and “fast growth and diffusive” group. A partially observable Markov chain can be formed
and it will apply some of the results found in this study in order to evaluate different follow-up
policies for recurring LGGs. Although validation of the proposed methods is difficult given limited
literature on LGG, we seek to apply our methods to other chronic diseases that have more research
on natural history modeling, e.g., breast cancer, for validation purposes.

33

Reference
Ankit
Rohatgi.
(n.d.).
WebPlotDigitizer.
http://arohatgi.info/WebPlotDigitizer/app/?

Retrieved

from

Chaichana, K. L., McGirt, M. J., Laterra, J., Olivi, A., al, E., & Quiñones-Hinojosa, A. (2010).
Recurrence and malignant degeneration after resection of adult hemispheric low-grade
gliomas. Journal of …, 112(1), 10–7. http://doi.org/10.3171/2008.10.JNS08608
Davidoff M.L. (1940). A thirteen year follow-up study of a series of cases of verified tumors of
the
brain.
Archives
of
Neurology
&
Psychiatry,
44(6),
1246–1261.
http://doi.org/10.1001/archneurpsyc.1940.02280120093009
Dept. of Radiation Medicine. (n.d.). History of Radiation Therapy. In UC San Diego School of
Medicine (pp. 259–286). UC San Diego School of Medicine. http://doi.org/10.1016/B978-07506-7516-1.00017-7
Drevelegas, A., & Papanikolaou, N. (2011). Imaging Modalities in Brain Tumors. In A.
Drevelegas (Ed.), (pp. 13–33). Berlin, Heidelberg: Springer Berlin Heidelberg. Retrieved
from http://link.springer.com/10.1007/978-3-540-87650-2_2
Forst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T. (2014). Low-Grade Gliomas. The
Oncologist, 19(4), 403–413. http://doi.org/10.1634/theoncologist.2013-0345
Grier, J. T. (2006). Low-Grade Gliomas in Adults. The Oncologist, 11(6), 681–693.
http://doi.org/10.1634/theoncologist.11-6-681
Guyot, P., Ades, A. E., Ouwens, M. J., & Welton, N. J. (2012). Enhanced secondary analysis of
survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC
Medical
Research
Methodology,
12(1),
9.
Retrieved
from
http://www.biomedcentral.com/1471-2288/12/9/
Kaplan, E. L., & Meier, P. (1958). Nonparametric estimation from incomplete observations.
Journal of the American Statistical Association, 53(282), 457–481.
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., … for the German
Glioma Network. (2007). Long-term survival with glioblastoma multiforme. Brain, 130(10),
2596–2606. http://doi.org/10.1093/brain/awm204
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., &
DePinho, R. A. (2001). Malignant glioma: genetics and biology of a grave matter. Genes &
Development, 15(11), 1311–1333. http://doi.org/10.1101/gad.891601
Mainio, A., Tuunanen, S., Hakko, H., Niemelä, A., Koivukangas, J., & Räsänen, P. (2006).
Decreased quality of life and depression as predictors for shorter survival among patients with
low-grade gliomas: A follow-up from 1990 to 2003. European Archives of Psychiatry and
Clinical Neuroscience, 256(8), 516–521. http://doi.org/10.1007/s00406-006-0674-2
34

McGirt, M. J., Chaichana, K. L., Attenello, F. J., Weingart, J. D., Than, K., Burger, P. C., …
Quinoñes-Hinojosa, A. (2008). Extent of surgical resection is independently associated with
survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery, 63(4),
700–707. http://doi.org/10.1227/01.NEU.0000325729.41085.73
Ostrom, Q. T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., … Barnholtz-Sloan, J.
(2014). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors
Diagnosed in the United States in 2007-2011. Neuro-Oncology, 16(suppl 4), iv1–iv63.
http://doi.org/10.1093/neuonc/nou223
Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., … Capelle, L.
(2013). Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse
low-grade gliomas. Neuro-Oncology, 15(5), 595–606. http://doi.org/10.1093/neuonc/nos331
Pignatti, F. (2002). Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade
Glioma.
Journal
of
Clinical
Oncology,
20(8),
2076–2084.
http://doi.org/10.1200/JCO.2002.08.121
Pouratian, N., & Schiff, D. (2010). Management of low-grade glioma. Current Neurology and
Neuroscience Reports, 10(3), 224–231. http://doi.org/10.1007/s11910-010-0105-7
Recht, L. D., & Bernstein, M. (1995). Low-grade gliomas. Neurologic Clinics, 13(4), 847–859.
http://doi.org/10.1212/01.CON.0000464174.88687.79
Rees, J., Watt, H., Jäger, H. R., Benton, C., Tozer, D., Tofts, P., & Waldman, A. (2008). Volumes
and growth rates of untreated adult low-grade gliomas indicate risk of early malignant
transformation.
European
Journal
of
Radiology,
72(1),
54–64.
http://doi.org/10.1016/j.ejrad.2008.06.013
Rosella Lorenzi. (2003, March). Brain tumor rates rising in Europe, US. Reuters Health.
Sanai, N., Chang, S., & Berger, M. S. (2011). Low-grade gliomas in adults. Journal of
Neurosurgery, 115(November), 948–965. http://doi.org/10.3171/2011.7.JNS101238
Schomas, D. A., Laack, N. N. I., Rao, R. D., Meyer, F. B., Shaw, E. G., O’Neill, B. P., … Brown,
P. D. (2009). Intracranial low-grade gliomas in adults: 30-year experience with long-term
follow-up
at
Mayo
Clinic.
Neuro-Oncology,
11(4),
437–45.
http://doi.org/10.1215/15228517-2008-102
Silverstein, M. D., Cascino, T. L., & Harmsen, W. S. (1996). High-grade astrocytomas: resource
use, clinical outcomes, and cost of care. Mayo Clinic Proceedings, 71(10), 936–944.
http://doi.org/10.4065/71.10.936
Smoll, N. R., & Hamilton, B. (2014). Incidence and relative survival of anaplastic astrocytomas.
Neuro-Oncology, 16(10), 1400–1407. http://doi.org/10.1093/neuonc/nou053
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., … Wick, W.
(2010). Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task
35

Force: Low-grade gliomas. European Journal of Neurology, 17(9), 1124–1133.
http://doi.org/10.1111/j.1468-1331.2010.03151.x
Stieber, V. (2001). Low-grade gliomas. Current Treatment Options in Oncology, 2(6), 495–506.
http://doi.org/10.1007/s11864-001-0071-z
Ye, C. Z., Yang, J., Geng, D. Y., Zhou, Y., & Chen, N. Y. (2002). Fuzzy rules to predict degree
of malignancy in brain glioma. Medical & Biological Engineering & Computing, 40(2), 145–
52. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12043794

36

Appendix
Numerical results of malignant transformation from recurring tumor.
Initial radius= 0.75cm

Initial Radius=1cm

Growth Rate/12 month

Distribution

6 month risk %

12 month risk %

6 month risk %

12 month risk %
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0.098280098
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Appendix (cont.)
Initial radius= 0.75cm
Growth Rate/12
month
3.60
3.70
3.80
3.90
4.00
4.10
4.20
4.30
4.40
4.50

Distribution
0
0.002457002
0
0
0
0
0.002457002
0
0
0

Weighted value=

Initial Radius=1cm

6 month risk
%
0.270797398
0.305485396
0.344001943
0.386703816
0.433975095
0.486228809
0.543908659
0.607490816
0.677485791
0.754440398

12 month risk
%
20.37284026
25.15833328
30.94801962
35.99494708
39.80730408
43.72700484
47.68655483
51.78734865
56.10737619
60.31050621

6 month risk
%
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